Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)
Glossary on
off
Printer Friendly Page Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

Clinicaltrials.gov identifier:
NCT04711109


Prevention study enrolling women ages 25-55 with a BRCA1 mutation

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

About the Study

NOTE: This study is no longer recruiting patients. 

The BRCA-P Study is an international research study for women who are born with a mutation (change) in one of their genes. The main purpose is to find out if the study medication, denosumab, can decrease the risk of developing breast cancer compared to a (inactive substance) in women with a gene mutation.

 

This Study is Open To:

NOTE: This study is no longer recruiting patients. 

 

This Study is Not Open To:

NOTE: This study is no longer recruiting patients.